Delving into the Latest Updates on Linrodostat with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Linrodostat (USAN), Linrodostat mesylate, BMS-986205

+ [5]

Target

IDO1

Action

inhibitors

Mechanism

IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)

Therapeutic Areas

NeoplasmsMouth and Tooth DiseasesOtorhinolaryngologic Diseases+ [3]

Active Indication

CarcinosarcomaRecurrent Endometrial CancerUterine Carcinosarcoma+ [6]

Inactive Indication

Acral Lentiginous Malignant MelanomaAdvanced gastric carcinomaAdvanced Lung Non-Small Cell Carcinoma+ [11]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H24ClFN2O

InChIKeyKRTIYQIPSAGSBP-ZACQAIPSSA-N

CAS Registry1923833-60-6

To inform I-O combination selection, messenger RNA expression analyses from The Cancer Genome Atlas evaluated associations between programmed death 1/programmed death ligand 1 (PD-1/PD-L1) and other I-O-associated genes. Tumor tissue blocks of melanoma, non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, and gastroesophageal junction/gastric cancer were stained by IHC to assess expression of CD8, colony-stimulating factor 1 receptor, glucocorticoid-induced tumor necrosis factor receptor (GITR), indoleamine 2,3-dioxygenase 1, lymphocyte-activation gene 3, NKp46, forkhead box P3, and PD-L1. These results facilitated an I-O treatment selection algorithm where patient biopsy results dictated allocation into combinations of nivolumab with cabiralizumab, urelumab, linrodostat mesylate, relatlimab, BMS-986156 (anti-GITR), lirilumab, ipilimumab, or irradiation. The primary endpoint was the proportion of patients with qualified baseline tumor biopsy specimens where decision-enabling biomarker analysis was completed within 12 business days to select an I-O combination therapy.

Results:

Correlation of PD-1/L1 and I-O-associated genes varied across the spectrum of T-cell-inflamed versus non-inflamed tumors; however, tumors with low/intermediatePD-L1expression demonstrated distinct upregulation of immune markers grouped by cell type (T cell, macrophage, etc). IHC analyses of I-O naïve tumors corroborated these findings with distinct immune target upregulation in low-to-intermediate inflamed tumors and significant associations between IHC-detected markers and T-cell inflammation score across most markers. In the clinical trial, 20/23 (87%) of eligible patients were successfully allocated and started on treatment within the 12-day window, meeting the primary endpoint. The safety profile appeared to generally align with those reported for the individual combinations from other trials. No treatment responses occurred. Most patients were allocated to the cabiralizumab treatment arm.

Conclusions:

Actualization of a patient-specific I-O combination treatment selection strategy is feasible, however, determination of de novo integral biomarker thresholds of novel I-O targets to facilitate effective treatment of PD-1-refractory cancer remains fraught. These data emphasize the difficulty of integral biomarker development for I-O in translating from immunotherapy treatment-naïve biospecimens to the selection of patients in the PD-1-refractory state.

Trial registration number:

NCT03335540.

03 Feb 2025·CLINICAL CANCER RESEARCH

Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma

Article

Author: Nikitina, Anastasia ; Scott, E. Reilly ; Argiris, Athanassios ; Sobol, Anastasia ; Sookiasian, Danielle ; Kushnarev, Vladimir ; Scher, Jessica ; Henao, Camilo ; Tyshevich, Andrey ; Gargano, Stacey ; Axelrod, Rita ; Llerena, Pablo ; Davitt, Christopher J.H. ; South, Andrew P. ; Old, Matthew ; Mann, Derek ; Alnemri, Angela ; Martinez-Outschoorn, Ubaldo ; Cognetti, David M. ; Seim, Nolan ; Tuluc, Madalina ; Tekumalla, Sruti ; Zhan, Tingting ; Johnson, Jennifer M. ; Mastrolonardo, Eric V. ; Chasse, Madison ; Harshyne, Larry A. ; Curry, Joseph M. ; Jegede, Victor ; Prendergast, George ; Nunes, Kathryn L. ; Luginbuhl, Adam J. ; Linnenbach, Alban J. ; Leiby, Benjamin E. ; Mahoney, My G.

Abstract:

Purpose::

We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders to immunotherapy and enhance their response.

Patients and Methods::

Patients with HNSCC were 3:1 randomized to receive nivolumab with or without BMS986205 orally daily (NCT03854032). In the combination arm, BMS986205 was initiated 7 days prior to nivolumab. Patients were stratified by human papillomavirus (HPV) status. Response-adaptive surgical timing involved response assessment by radiographic criteria 4 weeks after treatment with nivolumab in both arms. Nonresponders underwent surgical resection, whereas responders received 4 more weeks of randomized therapy before surgery. Biomarker analysis utilized pathologic treatment response (pTR) and RNA sequencing.

Results::

Forty-two patients were enrolled, and the addition of IDOi to nivolumab did not result in greater rate of radiographic response (P = 0.909). Treatment was well tolerated, with only 2 (5%) patients experiencing grade 3 immune-related adverse events. The addition of IDOi augmented rates of pTR in patients with high baseline IDO1 RNA expression (P < 0.05). Response-adaptive surgical timing demonstrated reliability in differentiating pathologic responders versus nonresponders (P = 0.009). A pretreatment NK cell signature, PD-L1 status, and IFN-γ expression in the HPV− cohort correlated with response. The HPV+ cohort found B-cell and cancer-associated fibroblast signatures predictive of response/nonresponse.

Conclusions::

Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting resistant nodes to immunotherapy. HPV status–dependent signatures predicting response to immunotherapy in HNSCC warrant further study.

01 Feb 2025·ESMO Open

Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study

Article

Author: He, A R ; Shankaran, V ; von Moos, R ; Geva, R ; Ku, G ; Greenawalt, D ; Gutierrez, M ; Sawyer, M B ; Yoon, H H ; Starr, J ; George, T J ; Denlinger, C S ; Lam, V K ; Di Bartolomeo, M ; Wang, Q ; Golan, T ; Elimova, E ; Lim, D ; Patel, A ; Aoyama, T ; Curigliano, G ; Fritsch, R ; Park, H ; Haag, G M ; Nagrial, A ; Lei, M ; Stein, S ; Kim, S S

BACKGROUND:

Nivolumab-based therapies are efficacious with acceptable safety in patients with gastric cancer (GC) and gastroesophageal junction cancer (GEJC). Novel nivolumab-based combination immunotherapies may offer enhanced efficacy in these indications. FRACTION-GC was a signal-seeking, randomized, open-label, phase II adaptive-design trial assessing efficacy and safety of nivolumab in combination with ipilimumab [cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody], relatlimab (lymphocyte-activation gene 3 antibody), or IDO1i (BMS986205, an indoleamine-2,3-dioxygenase-1 inhibitor) in patients with unresectable, advanced/metastatic GC/GEJC.

PATIENTS AND METHODS:

Previously treated patients with GC/GEJC were randomized to receive nivolumab + ipilimumab, nivolumab + relatlimab, or nivolumab + IDO1i across two tracks: anti-programmed death-(ligand) 1/anti-CTLA-4-naïve (track 1) and -experienced (track 2). Primary endpoints were objective response rate (ORR) by investigator per RECIST v1.1, duration of response, and progression-free survival (PFS) rate at 24 weeks. Secondary endpoint was safety.

RESULTS:

Eighty-one patients in track 1 and 81 in track 2 received one combination therapy. With a median follow-up of 50.2 months, ORR [95% confidence interval (CI)] by investigator for nivolumab + ipilimumab, nivolumab + relatlimab, and nivolumab + IDO1i in track 1 was 4% (0.1% to 21.9%), 5% (0.1% to 24.9%), and 13% (4.4% to 28.1%), and for track 2 was 9% (1.1% to 28.0%), 6% (0.7% to 18.7%), and 0% (0% to 15.4%), respectively. PFS rate at 24 weeks (95% CI) was 24% (11% to 39%) for nivolumab + IDO1i track 1, 17% (16% to 32%) for nivolumab + relatlimab track 2, and not estimable for other treatment arms. Grade 3/4 treatment-related adverse events were reported in 22%, 5%, and 18% of patients receiving nivolumab + ipilimumab, nivolumab + relatlimab, and nivolumab + IDO1i in track 1 and in 35%, 11%, and 18% of patients in track 2, respectively. No treatment-related deaths were reported.

CONCLUSIONS:

While ORR did not meet prespecified expansion criteria in any treatment arm, the safety profile of the combinations was manageable. FRACTION-GC represents a novel adaptive protocol for testing multiple combination immunotherapies.

8

News (Medical) associated with Linrodostat

28 Nov 2022

·www.businesswire.com

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering. This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets. Business Questions: How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer? Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward? What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer? Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity? If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor? Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC? Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why? How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent? If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC? What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed? For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl

Phase 2VaccineImmunotherapyClinical ResultASCO

09 Feb 2021

·www.globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade. “Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights: Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder's inner surface, wherein the bladder muscle is not involved. NMIBC Pipeline Therapies Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030. BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024. UGN-102: UroGen Pharma UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023. Atezolizumab: Hoffmann-La Roche Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028. To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report Scope of Non-Muscle Invasive Bladder Cancer Pipeline Report Coverage: Global Major Players: 30+ companiesProminent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBioKey Drugs: 30+ pipeline drugsNon-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202Phases Targets Mechanism of Action Molecule Types Route of Administration Product Types Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain. Table of Contents Related Reports Bladder Cancer Market DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bladder cancer, historical and forecasted epidemiology as well as the Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Muscle Invasive Bladder Cancer Market DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer Non-Muscle Invasive Bladder Cancer Market DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Multiple Myeloma Market DelveInsight’s ‘Multiple Myeloma (MM) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China. Non-Small Cell Lung Cancer Market DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Prostate Cancer Market DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adenoid Cystic Carcinoma Market DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Liver Cancer Market DelveInsight's "Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Pancreatic Cancer Market DelveInsight's "Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Advanced Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Pancreatic Adenocarcinoma Market DelveInsight's "Pancreatic Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CollaborateAntibody

27 Jan 2021

·www.globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade. “Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights: Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder's inner surface, wherein the bladder muscle is not involved. NMIBC Pipeline Therapies Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030. BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024. UGN-102: UroGen Pharma UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023. Atezolizumab: Hoffmann-La Roche Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028. To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report Scope of Non-Muscle Invasive Bladder Cancer Pipeline Report Coverage: Global Major Players: 30+ companiesProminent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBioKey Drugs: 30+ pipeline drugsNon-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202Phases Targets Mechanism of Action Molecule Types Route of Administration Product Types Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain. Table of Contents Related Reports Bladder Cancer Market DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bladder cancer, historical and forecasted epidemiology as well as the Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Muscle Invasive Bladder Cancer Market DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer Non-Muscle Invasive Bladder Cancer Market DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Multiple Myeloma Market DelveInsight’s ‘Multiple Myeloma (MM) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China. Non-Small Cell Lung Cancer Market DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Prostate Cancer Market DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adenoid Cystic Carcinoma Market DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Liver Cancer Market DelveInsight's "Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Pancreatic Cancer Market DelveInsight's "Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Advanced Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Pancreatic Adenocarcinoma Market DelveInsight's "Pancreatic Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CollaborateAntibody

100 Deals associated with Linrodostat

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11412	-	-	DB14986

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	United States	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	United States	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Japan	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Australia	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Austria	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Brazil	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Canada	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Czechia	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	France	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Germany	Bristol Myers Squibb Co.	24 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03695250 (CTgov)	Phase 1/2	Unresectable Hepatocellular Carcinoma	8	Nivolumab+IDO1 Inhibitor BMS-986205	acqeldhbqw = apsfjsakpa rgjtknyjta (hseucwjwit, axnjpquklt - jxccvosbmg) View more	-	22 Aug 2023
NCT03519256 (CheckMate 9UT, CTgov)	Phase 2	-	142	Nivolumab (Arm A: Nivolumab)	oqphggjrrv = pgodhhwtio oskgcpceoz (axiqwgskhi, qisqrhcsoc - ekyxmslfol) View more	-	01 Jun 2023
				BCG+Nivolumab (Arm B: Nivolumab Plus Intravesical BCG)	oqphggjrrv = bxcddzcuyc oskgcpceoz (axiqwgskhi, uvemumvrjt - ydktcpplfr) View more
NCT04106414 (CA017-056, ASCO2022) Manual	Phase 2	Recurrent Endometrial Cancer Maintenance	24	Nivolumab + BMS-986205	gchfpopvhw(fckfkjlcay) = snlkidujps wwaxiyzdkk (pdrmpzbuxl, 0.9 - 100) View more	Negative	02 Jun 2022
				Nivolumab	gchfpopvhw(fckfkjlcay) = ncrlmxuqbh wwaxiyzdkk (pdrmpzbuxl ) View more
NCT03854032 (CA017-087, ASCO2022) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck Neoadjuvant	42	nivolumab	jncoprwehy(kwhkkacfnj) = jryoamhouo ytwrgyuxtq (ottakklvqj )	Non-superior	02 Jun 2022
				Nivolumab+Linrodostat	jncoprwehy(kwhkkacfnj) = lgpyeyyxtt ytwrgyuxtq (ottakklvqj )
NCT03695250 (ASCO2022)	Phase 1/2	Hepatocellular Carcinoma First line	8	BMS-986205 + Nivolumab	ekbnzfioif(dphxnsxswc) = ksjdeehtti jozjfaohvd (pkolmbnvfl ) View more	Positive	02 Jun 2022
NCT03792750 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm \| Advanced cancer	12	Nivolumab+BMS-986205 (BMS-986205 in Combination With Nivolumab)	ixwjhjvnro = jojipfgrwp gkpioqorvo (adaljapqxb, vbhjhwvqch - relmmkecwx) View more	-	28 Feb 2022
				Nivolumab+BMS-986205 (BMS-986205 Monotherapy and in Combination With Nivolumab)	bduzkeccmk = fcoyvvdqyz fvujgpvoel (icjvmadizj, gchtgaoqaq - qavdmiztie) View more
NCT03329846 (CTgov)	Phase 3	Unresectable Melanoma	20	Nivolumab+BMS-986205	rojoucuyop = sdqllwscts mygnxoqrxq (kukoxhmuys, oaftdpvash - vrmhzwvssf) View more	-	09 Jul 2021
NCT02658890 (ASCO_GU 12019 \| ASCO_GU 22019) Manual	Phase 1/2	Bladder Cancer	516	BMS-986205+nivolumab	ijpwgcsqke(njasmsxtoa) = lfpecjgvyp snbijeuawr (iojglxgttn ) View more	Positive	15 Feb 2019
NCT02658890 (BMS-986205, SITC2017)	Phase 1/2	Advanced cancer kynurenine	216	BMS-986205 100 mg + Nivolumab 240 mg	fdrtigwakp(tlerxkzxjm) = rzbsbzkhed hzbgfgbisj (oayekepyhg ) View more	Positive	07 Dec 2017
				BMS-986205 200 mg + Nivolumab 480 mg	fdrtigwakp(tlerxkzxjm) = peecnnxgki hzbgfgbisj (oayekepyhg ) View more